Under the terms of the agreement Lonza may provide process development services for certain Medarex programmes and reserve manufacturing capacity for its antibody and antibody drug conjugate pipeline.
Lonza has cited the deal as evidence of its shift away from short-term product-by-product deals to long-term, strategic collaborations. By establishing such relationships the contract manufacturing organisation (CMO) should be able to reduce the revenue fluctuations that affect the sector.
The deal also leverages Lonza’s capacity in producing antibody drug conjugates, which are predicted to be a growth sector. Lonza has the capacity to produce milligram up to multiple kilogram batches for clinical and commercial supply.